Biovista and DART Therapeutics Enter into Drug Repositioning Collaboration Targeting Duchenne Muscular Dystrophy

March 26, 2013Press Releases

CHARLOTTESVILLE, Virginia and CAMBRIDGE, Massachusetts, March 26, 2013 /PRNewswire/ — DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy (DMD), and Biovista, a leader in systematic drug repositioning, announced today that they have entered into a research collaboration to identify and develop novel drug repositioning candidates for DMD … Read More

Biovista to host Drug Repositioning Workshop at 2nd World PGX Summit

March 20, 2012Events

CHARLOTTESVILLE, Virginia, March 20, 2012 — Biovista announced today that it will be organizing a workshop on drug repositioning at the upcoming World Pharmacogenomics Summit being held April 24-26 in Boston. The Workshop entitled “Understand How to Use PGx in Drug Repositioning, Adverse Event Prediction, Patient Subpopulation Stratification and Personalized Medicine” will help strategic level … Read More

Biovista Awarded Research Grant on Chronic Fatigue Syndrome From Solve ME/CFS Initiative

March 6, 2012Press Releases

CHARLOTTESVILLE, Virginia, March 6, 2012 /PRNewswire/ — Biovista announced today that it has been awarded a prestigious research grant by Solve ME/CFS Initiative to identify non-obvious mechanisms of the disease and potential drug repositioning candidates that will advance objective diagnosis and effective treatment of chronic fatigue syndrome (CFS). As part of its work, Biovista will share … Read More